Company newsGS
Explain this story: Why Iovance Biotherapeutics Stock Was on Fire Today
Iovance Biotherapeutics (NASDAQ: IOVA) saw its stock rise by almost 6% due to a bullish analyst report from Goldman Sachs. Analyst Andrea Newkirk resumed coverage, rating Iovance a "buy" with a $15 price target, citing strong Q2 performance of its drug Amtagvi and increasing demand as a second-line melanoma treatment. The report suggests that Amtagvi is entering a significant growth phase as operational hurdles are being overcome.
OtherThe Globe and MailSector and industry: FinancialsCapital MarketsTell me moreShow less
We have not explained this story yet. The original headline, summary and link are below.
Iovance Biotherapeutics (NASDAQ: IOVA) saw its stock rise by almost 6% due to a bullish analyst report from Goldman Sachs. Analyst Andrea Newkirk resumed coverage, rating Iovance a "buy" with a $15 price target, citing strong Q2 performance of its drug Amtagvi and increasing demand as a second-line melanoma treatment. The report suggests that Amtagvi is entering a significant growth phase as operational hurdles are being overcome.
Article tone: Positive This describes the words the journalist used. It is not a prediction, and not advice.